What Mineralys Therapeutics, Inc. told the SEC could break it.

Mineralys's lorundrostat targets hypertension — an indication with a very large Medicare-age population — exposing its future commercial economics to U.S. drug-pricing policy. The Inflation Reduction Act requires manufacturers of certain drugs to negotiate prices with Medicare beginning in 2026 (subject to a cap) and imposes Part B/Part D rebates; the ACA raised the Medicaid brand-drug rebate (15.1%→23.1% of AMP) and the American Rescue Plan removed the 100%-of-AMP Medicaid rebate cap from January 1, 2024. For a hypertension therapy likely to see heavy Medicare utilization, these regimes are a specific, material pricing/reimbursement exposure ahead of its expected launch. A distinct drug-pricing policy risk tied to the indication.

“the IRA requires manufacturers of certain drugs to engage in price negotiations with Medicare (beginning in 2026), with prices that can be negotiated subject to a cap”

Mineralys does not own or operate any manufacturing facilities for lorundrostat and has no plans to, depending entirely on third-party contract manufacturers for its required raw materials, active pharmaceutical ingredients, and finished product candidates for clinical (and eventually commercial) supply. As a single-product company whose NDA is pending (PDUFA target December 22, 2026), a CMO disruption, quality/cGMP failure, capacity constraint, or API-supplier interruption would directly stall its only asset, with no in-house fallback. The manufacturers are not named in the filing, so this is a sole-source/manufacturing-dependence risk rather than a named edge. A material single-product manufacturing-supply dependence.

“We currently depend on third-party contract manufacturers for our required raw materials, active pharmaceutical ingredients, and finished product candidates for our clinical trials.”